Lv62
2744 积分 2022-10-24 加入
New perspectives for targeting therapy in ALK-positive human cancers
11天前
已完结
ALK-positive lung cancer: a moving target
11天前
已完结
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
13天前
已完结
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
14天前
已完结
Optimization of METTL3 Inhibitors for the Treatment of Solid Tumors and AML
1个月前
已完结
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
1个月前
已完结
Discovery of Clinical Candidate IAG933, a Potent YAP-TEAD PPI Disrupter
2个月前
已完结
515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
3个月前
已完结
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
3个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3个月前
已完结
皖公网安备34019202002308
